Pharming Group N.V. (ENXTAM:PHARM) is looking acquisitions. During the company?s first half 2023 results call, Jeroen Wakkerman, Chief Financial Officer said that ?We continue to look at investments on acquisitions and in-licensing of mid- to late-stage opportunities in rare diseases to build the company further?.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.882 EUR | +1.03% | -1.84% | -14.45% |
05-08 | Transcript : Pharming Group N.V., Q1 2024 Earnings Call, May 08, 2024 | |
05-08 | Pharming Group N.V. Provides Revenue Guidance for 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.45% | 640M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- PHARM Stock
- News Pharming Group N.V.
- Pharming Seeks Acquisitions